CSIMarket Company Name, Ticker, Suppliers, else..
 
Skye Bioscience Inc   (NASDAQ: SKYE)
 
Price: $1.8093 $0.01 0.517%
Day's High: $1.8665000200271606 Week Perf: 2.51 %
Day's Low: $ 1.76 30 Day Perf: -10.21 %
Volume (M): 11,161 52 Wk High: $ 4.99
Volume (M$): $ 0 52 Wk Avg: $1.08
Open: $1.80 52 Wk Low: $0.25



 Market Capitalization (Millions $) 9
 Shares Outstanding (Millions) 5
 Employees 12
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -57
 Cash Flow (TTM) (Millions $) -38
 Capital Exp. (TTM) (Millions $) 0

Business Description


Skye Bioscience Inc is a biotechnology company focused on developing and commercializing novel therapeutics for various medical conditions. The company's primary area of research is the endocannabinoid system, which plays a crucial role in regulating various physiological processes. Skye Bioscience aims to leverage its expertise in this area to develop innovative drugs that target specific components of the endocannabinoid system to address unmet medical needs. The company's pipeline includes potential treatments for glaucoma, ocular inflammation, and neuroinflammatory conditions. Skye Bioscience is committed to advancing its drug candidates through rigorous clinical development and regulatory approval processes to bring transformative therapies to patients.


   Company Address: 11250 El Camino Real, San Diego 92130 CA
   Company Phone Number: 410-0266   Stock Exchange / Ticker: NASDAQ SKYE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        0.45% 
BMRN   -5.09%    
KROS   -1.14%    
PFE        3.46% 
SRPT   -8.44%    
VRTX        1.93% 
• View Complete Report
   



Shares

Skye Bioscience Bolsters Workforce with Strategic Inducement Grants and Board Appointment Amidst Market Challenges,

Published Thu, Feb 27 2025 11:01 PM UTC

Skye Bioscience Strengthens Talent Pool with Inducement Grants and Strategic Board Appointment Amidst Market ChallengesOverview of Recent Developments at Skye BioscienceIn a significant move to enhance its workforce and attract top-tier talent, Skye Bioscience, Inc. (Nasdaq: SKYE), a clinical-stage biopharmaceutical company dedicated to discovering new therapeutic pathways ...
Management Announcement

Skye Bioscience: Navigating the Road Ahead with Phase 2 Data and Market Challenges

Published Mon, Jan 13 2025 12:01 PM UTC

Skye Bioscience Inc. a trailblazer in the innovative realm of cannabinoid-based therapeutics, is gearing up for a significant year in 2025. As the company looks to unveil important Phase 2 clinical trial data related to its unique CB1 inhibitor for obesity, industry watchers are paying close attention. The anticipated results, expected in the second and fourth quarters of 20...
Clinical Study

Skye Bioscience Reaches Milestone in Innovative Obesity Treatment as Market Landscape Evolves

Published Thu, Nov 14 2024 12:00 PM UTC

In an impressive leap towards addressing the growing global obesity epidemic, Skye Bioscience, Inc. (Nasdaq: SKYE) has announced that it has surpassed the 50% patient enrollment mark in its Phase 2 clinical study known as CBeyond. The trial, which evaluates nimacimab a differentiated CB1 inhibitor aims to transform treatment options for individuals struggling with obesity an...
Clinical Study

In an era of rapid advancements and transformative breakthroughs, Skye Bioscience, Inc. stands at the nexus...

Published Fri, Nov 1 2024 11:00 AM UTC

Unlocking Potential Amidst Challenges: Skye Bioscience to Share Third Quarter 2024 Results In an era of rapid advancements and transformative breakthroughs, Skye Bioscience, Inc. stands at the nexus of innovation and resilience in the healthcare sector. As the San Diego-based clinical-stage biopharmaceutical company prepares to release its third-quarter financial results for...
Product Service News

A Glimmer of Hope in the Labyrinth of Loss The Promising Pursuits of Skye Bioscience

Published Mon, Sep 23 2024 11:01 AM UTC

In the grand tapestry of medical advancement, where the delicate threads of hope and despair often intertwine, the esteemed Skye Bioscience Inc. emerges as a daring voyager navigating the tempestuous seas of clinical trial outcomes. Aha, dear reader! Gather ’round, for we find ourselves at the confluence of ambition and apprehension, as Skye Bioscience, with unwavering res...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 1
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.64
Working Capital Ratio 1.78
Leverage Ratio (MRQ) 1.15
Total Debt to Equity 0.03
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -11.49 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 3.45 $
Book Value 1.82 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -4,777,571
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.